This bill would speed the development of psychedelic drugs and make it easier for patients to access them for serious mental illness. It is aimed at conditions such as treatment-resistant depression, PTSD, and other severe psychiatric disorders that have not responded well to existing therapies. The bill would likely work by directing federal health agencies to streamline research, approval, and access pathways, including issues that could affect veterans and other patients seeking new treatment options. Its reach would be strongest for patients, clinicians, researchers, and veterans involved in psychedelic-assisted therapy.
What This Bill Does
- Focuses on accelerating development of psychedelic drugs for serious mental illness.
- Aims to improve patient access to new treatment options beyond current therapies.
- Has been referred to Energy and Commerce, with additional referral to Judiciary and Veterans’ Affairs.
- Includes issues that could affect veterans and other patients seeking treatment.
- Has 3 cosponsors in the House.
Who This Bill Affects
For most Americans, this bill would not change day-to-day life right away. For people living with serious mental illness, treatment-resistant depression, PTSD, or similar conditions, it could eventually expand access to psychedelic-assisted therapies if those treatments are approved and made available through federal pathways. Veterans could be among the groups most directly affected if the bill leads to more research or access programs through VA-related channels.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Patients with treatment-resistant mental illness They argue that existing treatments do not help everyone and that psychedelic-assisted therapies could offer a new option for severe depression, trauma, and other hard-to-treat conditions. Faster development and access could mean relief sooner for people with few alternatives.
- Mental health clinicians and researchers They generally favor clearer federal pathways for clinical research and medical use because it can speed evidence gathering, standardize treatment, and reduce confusion for doctors. They see the bill as a way to bring promising therapies into a regulated system instead of leaving them stuck in a gray area.
- Veterans and veterans' advocates They may support the bill because veterans have high rates of PTSD, depression, and suicide risk, and current treatments do not always work well. Expanding carefully controlled access could create new options for those who have exhausted standard care.
- Public health and drug-safety advocates They worry psychedelic drugs can cause panic, psychosis, or other adverse mental health effects, especially without strict screening and supervision. They argue federal policy should not move faster than the science and safeguards.
- Some medical professionals They may object that enthusiasm for these drugs could outpace evidence on long-term safety, proper dosing, and who is most likely to benefit. Their concern is that rushed access could expose vulnerable patients to harm or inconsistent care.
- Law enforcement and regulatory skeptics They may fear that making these substances more available could complicate drug-control enforcement or blur the line between medical use and nonmedical use. Their concern is that expanded access could create diversion or public misunderstanding about safety.
Key Implications
-
““accelerate the development of, and access to, psychedelic drugs””
This signals a federal push to speed both research and patient availability. In practice, it could mean more studies, faster review pathways, and more pressure on agencies to create a medical framework for these treatments.
-
““could save lives and reverse the crisis of serious mental illness””
The bill is aimed at severe psychiatric conditions where existing treatments are often insufficient. That suggests the main beneficiaries would be patients with high-need diagnoses rather than the general public.
-
““for other purposes””
This broad legislative phrase often allows committees to consider related policy details, such as regulation, oversight, or implementation steps. It leaves room for agencies or Congress to add supporting provisions affecting how the therapies are supervised and used.
-
““Referred to the Committee on Energy and Commerce””
That committee generally handles health policy and drug regulation, so the bill is likely to be examined through a medical and public-health lens. Additional referrals indicate parts of the bill may also touch legal or veterans-related issues.
Official Source & Bill Facts
BillBoard checks this page against public Congress.gov metadata, then adds plain-English analysis where available.
- Bill
- HR 9559
- Congress
- 119th Congress
- Official title
- To accelerate the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States, and for other purposes.
- Policy area
- Healthcare
- Latest action
- Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (June 30, 2026)
- Last updated
- July 1, 2026
Latest Status
June 30, 2026
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Related Bills
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.